Share

November 14, 2017; 89 (20) ArticleOpen Access

The social and economic burden of frontotemporal degeneration

James E. Galvin, David H. Howard, Sharon S. Denny, Susan Dickinson, Nadine Tatton
First published October 4, 2017, DOI: https://doi.org/10.1212/WNL.0000000000004614
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
3137

Share

Article Information

vol. 89 no. 20 2049-2056
DOI: 
https://doi.org/10.1212/WNL.0000000000004614
PubMed: 
28978658
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received March 1, 2017
  • Accepted in final form August 25, 2017
  • First Published October 4, 2017.

Article Versions

Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. James E. Galvin, MD, MPH,
    2. David H. Howard, PhD,
    3. Sharon S. Denny, MA,
    4. Susan Dickinson, MSGC and
    5. Nadine Tatton, PhD
  1. James E. Galvin, MD, MPH,
    2. Scientific Advisory Boards:

    1. Phase 2 double-blind, placebo-controlled trial of Nilotinib in patients with mild to moderate AD. PI: R. Scott Turner, MD (Sponsor: Alzheimer Drug Discovery Foundation) 2016-present; Role: Chair, DSMB Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Alzheimer Disease. PI: Ana Pereira, MD (Sponsor: Alzheimer Drug Discovery Foundation) 2012-present; Role: Chair, DSMB A Preliminary Study of Carvedilol for the treatment of Alzheimer?s Disease (R01 AG00035546) PI: Paul Rosenberg, MD. (Sponsor: National Institute on Aging) 2011-present, Role: Member, DSMB

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Alzheimer disease and associated disorders, editorial board, 2005- present Neurodegenerative disease management, editorial board, 2012-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Axovant Biogen Lilly Eisai

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Axovant - clinical trial Biogen - clinical trial

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. David H. Howard, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. International Journal of Health Economics and Management, Editor-in-Chief, 2017

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Association for Frontotemporal Degeneration The Center for Discovery

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institutes of Health, PI, R01CA208758-01A1, 2017- Agency for Healthcare Research and Quality, PI, R03HS24613-01, 2016

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Robert Wood Johnson Foundation, 73800

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Sharon S. Denny, MA,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Susan Dickinson, MSGC and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Nadine Tatton, PhD
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) US 7,160,857 Tatton et al. Methods for increasing Schwann cell survival are disclosed. The methods of the invention are useful for the treatment of conditions such as peripheral neuropathies, including diabetic neuropathies.The present invention provides methods for increasing Schwann cell survival in a patient or in vitro, or for treating a peripheral neuropathy in a subject suffering from, or susceptable to, a peripheral neuropathy. (2) US 6,492,427 Shankar et al. Methods for treating multiple sclerosis. Methods for increasing oligodendrocyte survival are disclosed. The methods of the invention are useful for the treatment of Multiple Sclerosis. It has now been discovered that certain compounds are capable of increasing survival of oligodendrocytes. The invention provides methods for increasing survival of oligodendrocytes both in vivo and in vitro, of preventing or inhibiting death of oligodendrocytes, of preventing or inhibiting the progression of Multiple Sclerosis, and methods for treating Multiple Sclerosis.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Institute for Healthy Aging and Lifespan Studies (J.E.G.), Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton; Emory University (D.H.H.), Atlanta, GA; and Association for Frontotemporal Degeneration (S.S.D., S.D., N.T.), Radnor, PA.
  1. Correspondence to Dr. Galvin: galvinj{at}health.fau.edu
View Full Text

Article usage

Article usage: October 2017 to March 2021

AbstractFullPdfSource
Oct 2017281611060Highwire
Nov 20171938262256Highwire
Dec 20171309565Highwire
Jan 20186779134Highwire
Feb 2018698438Highwire
Mar 2018556751Highwire
Apr 20181264652Highwire
Apr 2018133948pmc
May 2018805747Highwire
Jun 20181288237Highwire
Jun 201861925pmc
Jul 20181964237Highwire
Aug 20181505139Highwire
Aug 2018153741pmc
Sep 2018585451Highwire
Oct 20181264419Highwire
Nov 20189526475Highwire
Dec 20181314329Highwire
Jan 2019189036Highwire
Feb 2019108725Highwire
Mar 2019915745Highwire
Apr 2019711150Highwire
May 2019309145Highwire
Jun 201969832Highwire
Jul 201988941Highwire
Aug 201926833Highwire
Sep 201956836Highwire
Oct 2019167137Highwire
Nov 2019266736Highwire
Dec 201966242Highwire
Jan 202065228Highwire
Feb 202096739Highwire
Mar 202086428Highwire
Apr 2020710650Highwire
May 2020169970Highwire
Jun 2020204950Highwire
Jul 202073618Highwire
Aug 202033333Highwire
Sep 2020129736Highwire
Oct 202097826Highwire
Nov 20201412346Highwire
Dec 2020129231Highwire
Jan 2021146229Highwire
Feb 2021148635Highwire
Mar 2021298156Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me